Logo

PGx and Biomarker Research Will Feature in Expanded J&J Facility in Pa.

Apr 20, 2007
NEW YORK (GenomeWeb News) — Johnson & Johnson Pharmaceutical Research and Development is expanding its facilities in Spring House, Pa., that will house drug-development research into biomarkers, structural biology, and pharmacogenomics, the company said yesterday.
 
The new facility, expected to be completed in 2009, will add around 150,000 square feet to the Spring House complex. The company said it plans to keep the 680 employees on the campus, and said it expects to hire 120 more.  

Breaking News
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.